Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.46 EUR | +0.63% | -.--% | -.--% |
Apr. 26 | Baloise shareholders vote in favor of scrapping 2% voting ceiling | RE |
Apr. 24 | Roche’s Downbeat Q1 Sales Drag Swiss Market Index to Red | MT |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company appears to be poorly valued given its net asset value.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The firm trades with high earnings multiples: 33.48 times its 2024 earnings per share.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 87.91B | - | ||
-6.03% | 113B | A- | ||
+20.96% | 63.76B | C | ||
+5.29% | 61.9B | - | B+ | |
+10.12% | 42.86B | C+ | ||
+7.95% | 40.84B | A- | ||
+18.92% | 34.58B | A- | ||
+5.88% | 25.48B | B | ||
-5.25% | 22.13B | A- | ||
+0.57% | 18.61B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UBSG Stock
- 0UB Stock
- Ratings UBS Group AG